

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number
WO 01/39795 A2

(51) International Patent Classification⁷: **A61K 38/46**,
38/51, A61P 17/00, 43/00

(74) Agents: PABST, Patrea, L. et al.; Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).

(21) International Application Number: PCT/US00/32399

(22) International Filing Date:
28 November 2000 (28.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/168,518 2 December 1999 (02.12.1999) US

(71) Applicant: **IBEX TECHNOLOGIES, INC.** [CA/US]; 5
Great Valley Parkway, Suite 300, Malvern, PA 19355 (US).

(72) Inventors: **DENHOLM, Elizabeth, M.**; 2 Victoria Avenue, Pointe Claire, Quebec H9S 4S3 (CA). **CAUCHON, Elizabeth**; 83 rue des Pins, Ile Perrot, Quebec J7V 8L6 (CA). **SILVER, Paul, J.**; 154 Barton Drive, Spring City, PA 19475-3418 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ATTENUATION OF FIBROBLAST PROLIFERATION

(57) Abstract: Highly purified and specific glycosaminoglycan degrading enzymes, chondroitinase B and chondroitinase AC, are used to treat fibroproliferative diseases. The enzymatic removal of chondroitin sulfate B (dermatan sulfate), and to a lesser extent, chondroitin sulfate A or C, from cell surfaces effectively decreases growth factor receptors on the cells and thereby decreases the cell proliferative response to such growth factors. In addition, removal of chondroitin sulfates reduces secretion of collagen, one of the major extracellular matrix components. Through the combined inhibition of fibroblast proliferation and collagen synthesis, treatment with chondroitinase B or chondroitinase AC decreases the size of fibrous tissue found in psoriasis, scleroderma, keloids, pulmonary fibrosis and surgical adhesions.



WO 01/39795 A2

ATTENUATION OF FIBROBLAST PROLIFERATION

Background of the Invention

The present invention is a method and composition using
5 chondroitinase B and chondroitinase AC, glycosaminoglycan degrading
enzymes, to inhibit the formation of fibrotic tissue.

Proteoglycans on the cell surface and in the extracellular matrix
contain variable glycosaminoglycan chains, which include heparan sulfate
and chondroitin sulfates A, B, or C. While some proteoglycans contain only
10 one type of glycosaminoglycan, others contain a mixture of heparan and
chondroitin sulfates (Jackson et. al., *Physiol. Rev.* 71:481-530,1991).
Extracellular proteoglycans form a structural framework for cells and tissues,
and together with cell-associated proteoglycans, have major functions in
regulating cell adhesion, migration, and proliferation. The functions of
15 proteoglycans and their component parts have been extensively studied, with
much of the emphasis on the roles of heparin and heparan sulfate on cell
metabolism (Kjellen, L., and Lindahl, U. (1991) *Ann. Rev. Biochem.*
60:443-475; Vlodavsky, et al. (1995) *Thrombosis Haemostasis* 74:534-540;
Yayon, et al. (1991) *Cell* 64:841-848)). Much less is known about the
20 biological activities of proteoglycans containing chondroitin sulfate
glycosaminoglycans, and in particular, their effects on cell proliferation.

Two inhibitors of glycosaminoglycan synthesis, chlorate and beta-
xyloside, have been used to examine the relative contributions of heparan
and chondroitin sulfate proteoglycans to control of the cell cycle (Keller, et
25 al. (1989) *Biochem.* 28:8100-8107; Miao, et al. (1995) *J. Cell. Biochem.*
57:713-184; Schwartz, N.B. (1977) *J. Biol. Chem.* 252:6316-6321).
However both of these compounds inhibit the expression of all types of
sulfated glycosaminoglycans. There are currently no inhibitors which can
selectively block the synthesis or expression of chondroitin sulfate A, B or C.
30 However, specific glycosaminoglycan lyases which can remove either
heparan or chondroitin sulfates A, B or C from cells are available.
Chondroitinases have been isolated from several bacterial species:

Flavobacterium heparinum, *Aeromonas* sp., *Proteus vulgaris*,
Aureobacterium sp. and *Bacillus thetaiotamicron* (Linhardt, et al. (1986) Appl.
Biochem. Biotech. 12:135-175; Linn, et al. (1983) J. Bacteriol. 156:859-866;
Michellacci, et al. (1987) Biochim. Biophys. Acta. 923:291-301; and Sato, et
5 al. (1986) Agric. Biol. Chem. 50:1057-1059).

Most studies examining the activities of chondroitin sulfate
proteoglycans (Lyon, et al. (1998) J. Biol. Chem. 273:271-278; Maeda, et al.
(1996) J. Biol. Chem. 271:21446-21452; Milev, et al. (1998) J. Biol. Chem.
273:21439-21442; Rapraeger, 1989, and Schmidt, et al. (1992) J. Biol.
10 Chem. 267:19242-19247) have utilized one such enzyme, chondroitinase
ABC (from *Proteus vulgaris*, Yamagata, et al. (1968) J. Biol. Chem.
243:1523-1535) which degrades all chondroitin sulfates (chondroitin sulfate
A, chondroitin sulfate C and chondroitin sulfate B). Since chondroitinase
ABC acts on more than one type of chondroitin sulfate, it is not possible to
15 determine the biological activity of the individual types of chondroitin
sulfates using this enzyme.

Evidence for a role of chondroitin sulfate A or B or C proteoglycans
in cell proliferation includes data which shows upregulation during rapid cell
proliferation, as occurs in wound healing (Penc and Gallo (1998) J. Biol.
20 Chem. 273:28116-28121; Yeo, et al. (1991) Amer. J. Pathol. 138:1437-1450)
and down regulation in quiescent cells (Tao et. al. (1997) Atherosclerosis
135:171-179). Such studies suggest that there may be a relationship between
the secretion and expression of cell surface chondroitin sulfate proteoglycans
and cell proliferation.

25 Recent studies in wound healing have found that chondroitin sulfate
B proteoglycans are present in high concentration in the fluid of healing
wounds, and that addition of these proteoglycans to a wounded area may
promote healing (Penc and Gallo, 1998). Although the mechanism of action
of the chondroitin sulfate B in wound healing is unknown, it is possible that
30 these proteoglycans may directly or indirectly affect cell proliferation.

It is therefore an object of the present invention to provide a method and compositions for treatment of conditions associated with abnormal formation of fibrous tissue, through modification of proteoglycans.

It is another object of the present invention to provide a method and
5 compositions to modulate collagen synthesis, decrease TGFbeta production, decrease fibroblast proliferation or migration, release chondroitin sulfate proteoglycans from cells, and decrease growth factor binding sites on fibroblasts.

It is a further object of the present invention to provide a method and
10 compositions to treat disorders which involve hyperproliferation of fibroblasts such as scleroderma, psoriasis, keloids, pulmonary fibrosis and surgical adhesions.

Summary of the Invention

Highly purified and specific glycosaminoglycan degrading enzymes,
15 chondroitinase B and chondroitinase AC, are used to treat fibroproliferative diseases. The enzymatic removal of chondroitin sulfate B, and to a lesser extent, chondroitin sulfate A or C, from cell surfaces effectively decreases growth factor receptors on the cells and thereby decreases the cell proliferative response to such growth factors. In addition, removal of
20 chondroitin sulfates reduces secretion of collagen, one of the major extracellular matrix components. Through the combined inhibition of fibroblast proliferation and collagen synthesis, treatment with chondroitinase B or chondroitinase AC decreases the size of fibrous tissue found in
25 psoriasis, scleroderma, keloids and surgical adhesions.

Brief Description of the Drawings

Figures 1A and 1B are graphs of the release of sulfated glycosaminoglycan from fibroblasts, following treatment with *Flavobacterium heparinum* derived Chondroitinase B, as a function of time
30 (Figure 1A) or dose (Figure 1B). Figure 1A shows the release of ³⁵S-glycosaminoglycans after treatment with 1.0 IU/ml of enzyme for the indicated time (min). Figure 1B shows the release of ³⁵S-

glycosaminoglycans after treatment with the indicated concentration of enzyme for one hr. Data are the cpm/well of ^{35}S -glycosaminoglycans released by enzyme treatment (cpm enzyme treated cells minus cpm cells treated with medium alone), from a representative of two such experiments performed in triplicate. Mean cpm released by medium alone was $8,160 \pm 599$.

Figure 2 is a graph of the time and dose dependent release of sulfated glycosaminoglycans from fibroblasts following treatment with *Flavobacterium heparinum* derived Chondroitinase AC. Solid bars represent release after a one hr treatment, and open bars are release after a 2 hr treatment. Data are the cpm/well of ^{35}S -glycosaminoglycans released by enzyme treatment (cpm enzyme treated cells minus cpm cells treated with medium alone), from a representative of two such experiments performed in triplicate. Mean cpm released by medium alone was $4,028 \pm 54$.

Figures 3A and 3B are graphs of the binding of ^{125}I -bFGF to fibroblast glycosaminoglycans (GAGs, Figure 3A) and bFGF receptors (Figure 3B) following treatment with *Flavobacterium heparinum* derived Chondroitinase B. Total (triangles), nonspecific (o) and specific (•) binding are shown. Data is from a representative of five such experiments performed in duplicate.

Figure 4 is a graph of the Scatchard analysis of bFGF bound to receptors of fibroblasts treated with medium (control, •) or 1.0 IU/ml of *Flavobacterium heparinum* derived chondroitinase B (o). Data are from a representative of five such experiments performed in duplicate.

Figures 5A and 5B are graphs of the dose dependent effects of *Flavobacterium heparinum* derived chondroitinase B (Figure 5A) and chondroitinase AC (Figure 5B) on fibroblast proliferation in response to 10% fetal bovine serum (serum) (•) or 100 pg/ml bFGF (o). Data are the % inhibition of proliferation for cells treated with chondroitinase B compared to cells treated with medium alone. Each point is the mean \pm sem of four experiments performed in triplicate.

Figure 6 is a graph of the collagen content of the extracellular matrix of fibroblasts treated with 0 to 10 IU/ml of *Flavobacterium heparinum* derived chondroitinase B, in the absence (cross hatched) or presence (black) of 25 ng/ml TGF-beta.

5 Figure 7 is a graph of the inhibition of cell proliferation in mouse skin cultures treated for 8 days with 0.1 to 10 IU/ml of *Flavobacterium heparinum* derived chondroitinase B. Proliferation was assessed by the incorporation of 3H-thymidine into skin sections following a 24 hr exposure. Data are expressed as % inhibition when compared to controls (no enzyme).
10 Each bar represents the mean \pm sem of 36 skin sections, taken from 3 mice. The * indicates inhibition was statistically significant with $p < 0.05$.

 Figure 8 is a graph of the decrease in dermal thickness in mouse skin cultures treated for 8 days with 0.1 to 10 IU/ml of *Flavobacterium heparinum* derived chondroitinase B. Data are expressed as % decrease
15 compared to controls (no enzyme). Each bar represents the mean \pm sem of measurements taken from 18 skin sections, from 3 mice. The * indicates that inhibition (decrease in thickness) was statistically significant with $p < 0.05$.

 Figures 9a and 9b are graphs of the inhibition of the expression of mRNA for procollagen I (Figure 9a) and TGF β (Figure 9b) in the lungs of
20 mice treated with Chondroitinase B. Treatment groups indicate the route and substance injected into the trachea/ or peritoneal cavity respectively. ChB is 25 IU of enzyme per injection; BLM is one injection of 0.025 units of bleomycin sulfate; and SAL indicates the injection of equal volumes of saline. Data are expressed as integration units ($\times 10^3$) as determined by densitometry readings
25 of Northern blot films. Each bar represents the mean \pm sem of 6 mice. The * indicates the decrease in mRNA expression was significantly less than that found in mice given BLM/SAL.

Detailed Description of the Invention

30 Glycosaminoglycans, including chondroitin sulfates A, B or C, and heparan sulfate, are the sulfated polysaccharide components of proteoglycans located on cell surfaces, where they act as co-receptors for cytokines and

growth factors and in the extracellular space where they form the structure of the extracellular matrix and serve as a supporting and organizational structure of tissues and organs.

Two ultra-purified enzymes from *Flavobacterium heparinum*,
5 chondroitinase B whose sole substrate is chondroitin sulfate B, and
chondroitinase AC whose substrates are chondroitin sulfate A and C, have
made it possible to distinguish between the activities of the different
chondroitin sulfates and to directly assess their influence on human skin
fibroblast proliferation. Starting from the premise that chondroitin sulfate
10 proteoglycans promote cell proliferation, it has now been demonstrated that
removal of chondroitin sulfate B, and, to a lesser extent, chondroitin sulfate
A or C, inhibits cell proliferation.

The method for inhibiting events in the fibrotic process by the use of
a highly purified glycosaminoglycan degrading enzyme, preferably from
15 *Flavobacterium heparinum*, is demonstrated in the examples.

Enzyme Formulations

Enzymes

The chondroitinase B and chondroitinase AC described in the
examples are glycosaminoglycan degrading enzymes from *Flavobacterium*
20 *heparinum*. Both enzymes modulate the interactions involved in cell
proliferation and extracellular matrix synthesis by i) releasing chondroitin
sulfate proteoglycans from cells; ii) decreasing growth factor binding sites on
cells; iii) decreasing fibroblast proliferation ; iv) decreasing TGFbeta
production, and v) decreasing collagen synthesis and thereby decreasing
25 fibrous tissue formation.

Glycosaminoglycans are unbranched polysaccharides consisting of
alternating hexosamine and hexuronic residues which carry sulfate groups in
different positions. This class of molecules can be divided into three families
according to the composition of the disaccharide backbone. These are:
30 heparin/heparan sulfate [HexA-GlcNAc(SO₄)]; chondroitin sulfate [HexA-
GalNAc]; and keratan sulfate [Gal-GlcNAc].

Representative glycosaminoglycan degrading enzymes include heparinase 1 from *Flavobacterium heparinum*, heparinase 2 from *Flavobacterium heparinum*, heparinase 3 from *Flavobacterium heparinum*, chondroitinase AC from *Flavobacterium heparinum*, and chondroitinase B from *Flavobacterium heparinum*, heparinase from *Bacteroides* strains, heparinase from *Flavobacterium* Hp206, heparinase from *Cytophagia* species, chondroitin sulfate degrading enzymes from *Bacteroides* species, chondroitin sulfate degrading enzymes from *Proteus vulgaris*, chondroitin sulfate degrading enzymes from *Micrococcus*, chondroitin sulfate degrading enzymes from *Vibrio* species, chondroitin sulfate degrading enzymes from *Arthrobacter aureus*, these enzymes expressed from recombinant nucleotide sequences in bacteria and combinations thereof. Other enzymes which degrade glycosaminoglycans are present in mammalian cells and include heparanases, arylsulfatase B, N-acetylgalactosamine-6-sulfatase, and iduronate sulfatase.

The chondroitin sulfate family includes seven sub-types designated unsulfated chondroitin sulfate, oversulfated chondroitin sulfate and chondroitin sulfates A-E which vary in the number and position of their sulfate functional groups. Additionally, chondroitin sulfate B, also referred to as dermatan sulfate, differs in that iduronic acid is the predominant residue in the alternative hexuronic acid position.

Chondroitin sulfates A, B and C are the predominant forms found in mammals and may be involved in the modulation of various biological activities including cell differentiation, adhesion, enzymatic pathways and hormone interactions. The presence of chondroitin sulfate proteoglycans is elevated in the later stages of cell growth in response to tissue and vessel damage, as reported by Yeo, et al., *Am. J. Pathol.* 138:1437-1450, 1991, Richardson and Hatton, *Exp. Mol. Pathol.* 58:77-95, 1993 and Forrester, et al., *J. Am. Coll. Cardiol.* 17:758-769, 1991. Chondroitin sulfates also have been associated with events involved in the progression of vascular disease and lipoprotein uptake as described by Tabas, et al., *J. Biol. Chem.*, 268(27):20419-20432, 1993.

Chondroitinases have been isolated from several bacterial species:

Flavobacterium heparinum, *Aeromonas sp.*, *Proteus vulgaris*,
Aureobacterium sp. and *Bacillus thetaiotamicron* (Linhardt et. al., 1986; Linn
et. al., J. Bacteriol. 156:859-866, 1983; Michelacci et. al., Biochim. Biophys.
5 Acta. 923:291-201, 1987; and Sato et. al., Agric. Biol. Chem. 50:1057-1059,
1986). PCT/US95/08560 "*Chondroitin Lyase Enzymes*" by Ibex
Technologies R and D, Inc., et al. describes methods for purification of
naturally produced chondroitinases, especially separation of chondroitinase
AC from chondroitinase B, as well as expression and purification of
10 recombinant chondroitinases. Mammalian enzymes which degrade
chondroitin sulfates include arylsulfatase B, N-acetylgalactosamine-6-
sulfatase, and iduronate sulfatase.

Those enzymes useful in the methods and compositions described
herein will cleave proteoglycans on the surfaces of cells, in particular
15 fibroblasts, most preferably those which serve as receptors involved in cell
proliferation and/or migration and/or gene expression, particularly of
collagen.

Formulations

For topical application, the glycosaminoglycan degrading enzyme is
20 combined with a carrier so that an effective dosage is delivered, based on the
desired activity, at the site of application. For topical application, several
ointments and cremes are currently used for other therapeutics agents; any
one of which can be used for the application of chondroitinase B or AC. The
topical composition can be applied to the skin for treatment of diseases such
25 as psoriasis. The carrier may be in the form of an ointment, cream, gel,
paste, foam, aerosol, suppository, pad or gelled stick. For topical application,
several ointments and cremes are currently used for other therapeutics
agents; any one of which can be used for the application of chondroitinase B
or AC. A topical composition consists of an effective amount of
30 glycosaminoglycan degrading enzyme in a pharmaceutically acceptable
excipient such as buffered saline, mineral oil, vegetable oils such as corn or

arachis oil, petroleum jelly, Miglyol 182, alcohol solutions, or liposomes or liposome-like products.

Compositions for local or systemic administration will generally include an inert diluent. For example, for injection, chondroitinase B or AC
5 can be prepared in physiological balanced buffer solutions. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents
10 such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of
15 glass or plastic.

For directed internal topical applications, the composition may be in the form of tablets or capsules, which can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as
20 starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; or a glidant such as colloidal silicon dioxide. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials
25 which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents. Any of these formulations may also include preservatives, antioxidants, antibiotics, immunosuppressants, and other biologically or pharmaceutically effective agents which do not exert a detrimental effect on the glycosaminoglycan degrading enzyme or cells.

30 The glycosaminoglycan degrading enzyme can also be administered in combination with a biocompatible polymeric implant which releases the glycosaminoglycan degrading enzyme over a controlled period of time at a

selected site. Examples of preferred biodegradable polymeric materials include polyanhydrides, polyorthoesters, polyglycolic acid, polyesters such as polylactic acid, polyglycolic acid, polyethylene vinyl acetate, and copolymers and blends thereof. Examples of preferred non-biodegradable polymeric materials include ethylene vinyl acetate copolymers.

Other Therapeutic Agents which can be Administered in Combination

The glycosaminoglycan degrading enzymes can be administered alone or in combination with other treatments. For example, the enzymes can be administered with antibiotics, antibodies to cytokines and chemokines (such as TNFalpha, TGFbeta, Il-1, Il-6), and anti-inflammatory such as cortisone.

Other combinations will be apparent to those skilled in the art.

Methods of Treatment

Excessive cell proliferation is characteristic of chronic diseases such as psoriasis, scleroderma and pulmonary fibrosis. Each of these diseases represents a complex interaction of the individual cell types composing the involved organ. In general terms these diseases are characterized by uncontrolled cell proliferation and the deposition of excess collagen and glycosaminoglycans (Liu and Connolly (1998) Sem. Cutaneous Med. and Surg. 17:3-11; and Phan, S.H. Fibrotic mechanisms in lung disease. In: Immunology of Inflammation, edited by P.A. Ward, New York: Elsevier, 1983, pp121-162). Although collagen is considered to be the major component of fibrotic scar tissue, recent work has indicated that sulfated glycosaminoglycans may be crucial to the process of collagen deposition and tissue remodeling which occurs in such diseases (Bensadoun, et al. (1996) Amer. J. Respir. Crit. Care Med. 154:1819-1828). A key cell in all these diseases is the fibroblast. Fibroblast proliferation and matrix secretion are responsible for much of the increase in tissue thickness and density. Fibroblasts make a major contribution to the excessive scar tissue in post-surgical adhesions, and in keloids which form after injuries such as burns. The mechanisms controlling fibroblast proliferation and secretion of collagen and glycosaminoglycans are complex. substances

which activate fibroblasts include cytokines, chemokines and growth factors, produced by other cells, and by fibroblasts themselves. One such cytokine is TGF-beta, considered to be a key controller of collagen synthesis. TGF-beta is secreted by fibroblasts and can feedback to enhance its own secretion, increasing both fibroblast matrix production and proliferation. TGF-beta activities are mediated through the interaction of specific receptors, sulfated glycosaminoglycans associated with them, and with other matrix proteins (Segarini, et al. (1989) Molecular Endocrinol. 3:261-272).

As demonstrated by the examples, the glycosaminoglycan degrading enzyme is administered to the site to be treated in a dosage effective to modulate collagen synthesis, fibroblast proliferation or migration, release chondroitin sulfate proteoglycans from cells; decrease growth factor binding sites on cells, and thereby decrease fibrous tissue formation, as appropriate for the specific application. Application is either topical, localized, sub-dermal or systemic.

Chondroitinase B or chondroitinase AC can be applied topically, for example, to lesions of scleroderma, psoriasis and keloids; or injected sub-dermally (locally), for example, into keloids and surgical adhesions. These chondroitinases may also be used systemically to treat pulmonary fibrosis, either via intravenous injection or via aerosol administration directly into the lungs.

Examples

The present invention will be further understood by reference to the following non-limiting examples.

25 Example 1: Enzyme substrate specificity.

Chondroitinase B (no EC number) and chondroitinase AC (EC 4.2.2.5) are recombinant proteins expressed in *Flavobacterium heparinum* (PCT/US95/08560 "Chondroitin Lyase Enzymes"). Specific activity and substrate specificity were determined for each enzyme, using a kinetic spectrophotometric assay, performed essentially as described in PCT/US95/0856. In these assays, enzyme concentrations were 0.25 IU/ml and substrate concentrations were 0.5 mg/ml (chondroitin sulfate B and

chondroitin sulfate AC) or 0.75 mg/ml (heparan sulfate). The specific activities of the enzymes were: 97 IU/mg for Chondroitinase B and 221 IU/mg for chondroitinase AC.

The substrate specificity of ultra-purified Chondroitinase B and AC were determined by testing the ability of the enzymes to degrade chondroitin sulfate B, chondroitin sulfate A, chondroitin sulfate C, and heparan sulfate. As shown in Table 1, both enzymes were active towards the corresponding sulfated glycosaminoglycan, with 0.2% or less activity against any of the other glycosaminoglycans. These results confirm the substrate specificity of the purified Chondroitinase B and Chondroitinase AC used in this application.

Table 1: Comparative Enzymatic Activities Against Glycosaminoglycans

<u>Enzyme</u>	<u>Substrate</u>			
	<u>CSB</u>	<u>CSA</u>	<u>CSC</u>	<u>HS</u>
<u>Chondroitinase B</u>				
IU/ml	399	0.04	0.03	0.92
(relative activity)	(100)	(0.01)	(0.01)	(0.23)
<u>Chondroitinase AC</u>				
IU/ml	0.604	1238	735	2.2
(relative activity)	(0.05)	(100)	(59)	(0.18)

Enzyme activities are shown as IU/ml with each substrate, and as the relative activity towards each substrate. Relative activity was determined after assigning 100% for the preferred substrate (CSB for chondroitinase B, CSA for chondroitinase AC. CSB=chondroitin sulfate B; CSA=chondroitin sulfate A; CSC=chondroitin sulfate C; HS=heparan sulfate. Substrate concentrations were 500 mcg/ml (CSB, CSA, CSC) or 750 mcg/ml (HS).

Example 2: Removal of glycosaminoglycans from cells

The effectiveness of the chondroitinases B and AC in removing sulfated glycosaminoglycans from cells was examined using cells with glycosaminoglycans labeled by incubation with ³⁵S. Fibroblasts were plated

at a density of 6×10^4 cells/well in 24 well plates, in DMEM with 10% serum. After 24 hrs, medium was changed to Fisher's medium containing 10% serum and 25 microCi/ml of $\text{Na}_2^{35}\text{SO}_4$, and incubation continued for 2.5 days. The medium was removed and cells rinsed 2X with DMEM then
5 treated with Chondroitinase B or AC as indicated. Medium was removed and radioactivity determined. The release of sulfated glycosaminoglycans from cells by enzyme was expressed as cpm/well of chondroitinase-treated cells minus cpm/well of untreated cells.

Cells were exposed to 1.0 IU/ml of Chondroitinase B, at 37°C for
10 variable lengths of time. As shown in Figure 1A, maximal release of sulfated GAGs by chondroitinase B was achieved following an 1 hour exposure to enzyme. Further experiments were done, in which fibroblasts were treated for 1 hour with varying concentrations of Chondroitinase B. Figure 1B illustrates that the release of sulfated glycosaminoglycans from
15 fibroblasts was also dependent on the concentration of chondroitinase B used.

The release of sulfated GAGs by chondroitinase AC was examined by treating fibroblasts for 1 or 2 hrs with 0.1 and 1.0 IU/ml of enzyme. As shown in Figure 2, the release of sulfated GAGs by chondroitinase AC was
20 both time and dose dependent. Maximal release was achieved after a 2 hr treatment with 1.0 IU/ml of enzyme.

Example 3: Effects on bFGF binding

Iodinated bFGF was obtained from Dupont NEN, specific activity greater than 1200 Ci/mmol. Fibroblasts were plated in 48 well dishes and
25 grown to confluence. Prior to binding assays, cells were treated with medium or enzyme as indicated for proliferation assays. Following enzyme treatments, cells were chilled and binding assays carried out at 4°C. Cells were incubated for one hour with 25 ng/ml of ^{125}I -bFGF alone, or with the addition of 25 microg/ml of unlabelled bFGF in binding buffer (DMEM,
30 25mM HEPES, 0.05% gelatin). Following incubation with bFGF, cells were washed 2X with ice cold binding buffer. Glycosaminoglycan-bound ^{125}I -bFGF was removed with two rinses with wash buffer (2M NaCl in 20mM

HEPES, pH 7.4). Receptor bound ^{125}I -bFGF was removed by washing 2X with wash buffer (pH 4.0) (Fannon and Nugent (1996) J. Biol. Chem. 271:17949-17956).

5 Numerous growth factors have been shown to bind to heparan sulfate proteoglycans on the cell surface. There is however little information on growth factor binding to chondroitin sulfate proteoglycans. The effects of chondroitinase B and chondroitinase AC on the binding of one such growth factor (bFGF), to fibroblasts was therefore examined. On chondroitinase B-treated cells, the amount of bFGF bound to both cell surface
10 glycosaminoglycans and receptors decreased as the concentration of enzyme increased (Figure 3). Specific binding to glycosaminoglycans was significantly decreased by $51 \pm 6\%$ ($n=3$), at the highest concentration of enzyme used (10 IU/ml). Receptor binding was significantly decreased by $32 \pm 9\%$ and $31 \pm 8\%$ ($n=3$) at 1.0 and 10 IU/ml respectively.

15 Scatchard plot analysis of bFGF binding data found a decrease in the number of receptors on chondroitinase B-treated cells when compared to controls, with no change in binding affinity (Figure 4). Chondroitinase B-treated fibroblasts had $1.8 (\pm 0.6) \times 10^5$ receptors while untreated fibroblasts had $3.0 (\pm 0.8) \times 10^5$ receptors. The binding affinity in chondroitinase-
20 treated fibroblasts was 15.3 ± 3.6 nM, compared to 16.7 ± 2.9 nM in controls, ($n=5$).

Chondroitinase AC was less effective in inhibiting bFGF binding to fibroblasts. Binding of bFGF was unaffected by 0.01 to 1.0 IU/ml of chondroitinase AC, though significant inhibition was found with 10 IU/ml.
25 At 10 IU/ml of chondroitinase AC, specific binding to GAGs and receptors was inhibited by $46 \pm 2\%$, and $54 \pm 3\%$, respectively.

Example 4: Effects on proliferation.

Human dermal fibroblasts were obtained from Clonetics, Inc., San Diego, CA. Cells were cultured in DMEM containing 1% antibiotics and
30 10% serum. The proliferation assay was performed as previously described (Denholm and Phan (1989) Amer. J. Pathol., 134:355-363). Briefly, cells were plated in DMEM w/10% serum; 24 hrs later medium was replaced with

serum free medium, and incubation continued for an additional 24 hrs. Cells were then treated with either serum free DMEM alone, or DMEM containing the indicated concentration of enzyme for 1 hour at 37°C. Following enzyme treatment, cells were rinsed 1X with DMEM, then given DMEM w/10% serum and incubated for 48 hrs. In experiments using bFGF, DMEM containing 2 mg/ml BSA was used, with or without 100 pg/ml bFGF. Controls for each experiment were: (negative) untreated cells incubated in serum free medium, and (positive) untreated cells incubated in DMEM w/10% serum. The number of cells per well was quantitated using the CyQuant assay method from Molecular Probes, Eugene, OR. Fluorescence/well was determined using a CytoFluor Series 4000 fluorescent plate reader (PerSeptive Biosystems) and cell numbers calculated from a standard curve. The average number of cells/well in negative controls was $3.0 \pm 0.3 \times 10^4$, and for positive controls was $9.0 \pm 0.8 \times 10^4$ (mean \pm sem; n = 10). Based on controls for each experiment, data is represented as % Inhibition, where: % Inhibition = $1 - [\text{\#cells/well enzyme-treated} / \text{\#cells/well untreated}] \times 100\%$.

Experiments were performed to determine if treatment of fibroblasts with chondroitinase B or chondroitinase AC would have an effect on proliferation of these cells. Proliferation of fibroblasts in response to 10% fetal bovine serum (serum) was inhibited in a dose dependent manner when cells were pretreated for 1 hour with 0.01 to 10 IU/ml of Chondroitinase B (Figure 5A, closed circles). Maximal inhibition of proliferation with chondroitinase B treated fibroblasts was 47 to 63% at 0.3 to 10 IU/ml. Chondroitinase AC treatment of fibroblasts also inhibited the proliferative response to serum in a dose dependent manner (Figure 5B, closed circles). Inhibition of 19 to 44% was found at doses of 1.0 to 10 IU/ml of chondroitinase AC.

Since binding experiments had revealed that treatment with chondroitinase B and chondroitinase AC had decreased bFGF binding to fibroblasts, the fibroblast proliferation experiments were repeated using bFGF in place of serum. Removal of chondroitin sulfate B with

chondroitinase B inhibited the proliferative response to bFGF, in a dose dependent manner (Figure 5A, open circles). Inhibition of proliferation in response to bFGF, however, required higher concentrations of enzyme than were needed to inhibit the response to serum. No inhibition was observed at
5 chondroitinase B concentrations below 1.0 IU/ml; maximal inhibition was $26 \pm 4\%$ at a concentration of 10 IU/ml. There was a significant correlation between the effects of chondroitinase B on bFGF binding to its receptor and the effects on cell proliferation ($r^2 = 0.987$, $p < 0.003$).

Chondroitinase AC treatment of fibroblasts had little effect on the
10 proliferation of fibroblasts in response to bFGF (Figure 5B, open circles). As with bFGF binding, 10 IU/ml of chondroitinase AC was required to detect inhibition of proliferation.

Example 5: Inhibition of collagen synthesis in fibroblasts

The effects of Chondroitinase B on the synthesis and secretion of
15 collagen were examined in an ELISA assay. Human dermal fibroblasts were plated into 96 well plates at a density of 1×10^4 cells/well, in medium with 10% serum. Three days later, medium was changed to serum-free medium containing 50 μ g/ml of ascorbic acid, and incubation continued for 24 more hours. Cells were treated for 1 hour with 0 to 10 IU/ml of Chondroitinase B,
20 then washed 1X with serum-free medium, and given fresh medium with ascorbic acid with or without 25 ng/ml TGF-beta. Fibroblasts were then incubated 72 hours at 37°C. Medium was removed from cells, and cells were lysed by adding a solution of 0.02M NH_4OH and 0.5% Triton in phosphate buffered saline (PBS) for 5 mins. The remaining extracellular
25 matrix was washed 2X with PBS. Collagen content of the extracellular matrix was assayed using a direct ELISA, using monoclonal mouse anti-human type I collagen as the primary antibody and horseradish peroxidase conjugated goat anti-mouse antibody as the secondary antibody. Collagen was quantitated by reading absorbance at 450 nm on a multiwell
30 spectrophotometer. The amount of collagen per well was calculated from a standard curve of varying concentrations of human type I collagen.

As shown in Figure 6, Chondroitinase B inhibited collagen secretion and incorporation into the extracellular matrix. The amount of collagen in the matrix of fibroblasts treated with 1 and 10 IU/ml of Chondroitinase B was significantly less than that of untreated cells. This effect was more pronounced with cells for which collagen synthesis had been stimulated with TGF β .

Example 6: Inhibition of fibroblast proliferation in mouse skin organ cultures.

Skin from Flaky skin mice (fsn/fsn) was used in these experiments. Flaky skin mice are a spontaneous mutant strain which develop skin lesions very similar to those seen in human psoriasis. (Sunderberg, et al. (1997) Pathobiology 65:271-286). The skin of these mice is noticeably thickened and scaly by 7 weeks of age. Histological examination shows extensive thickening of the epidermal layers, as well as the dermis. The increase in the dermis is due to the hyperproliferation of fibroblasts and an increase in collagen synthesis by these cells. Any pharmacological agent which decreases dermal thickness may have utility in treating diseases such as psoriasis and scleroderma.

Flaky skin organ cultures were utilized to evaluate the effects of Chondroitinase B on fibroblast proliferation and dermal thickening. Cultures were initiated and maintained, as has been described previously for human skin cultures (Varani, et al. (1994) Amer. J. Pathol. 145:561-573). Skin was obtained from 7 to 9 week old mice. Skin was washed 2X in DMEM containing a 5X concentration of penicillin/streptomycin to prevent contamination of cultures with bacteria. Under sterile conditions, skin was cut into two mm² sections, and one section was placed in each well of 96 well dishes, along with 0, 0.1, 1.0 or 10 IU/ml of Chondroitinase B in Keratinocyte Growth Medium (Clonetics) containing 1.5 mM calcium. These cultures were maintained for 8 days, with a change of medium on days 1, 4 and 6.

On day 0, 3 and 7, some cultures were pulsed with 1 μ Ci of ³H-thymidine and harvested 24 hours later (day 1, 4, and 8). Thymidine labeled

sections were used to assess fibroblast proliferation, measured by the incorporation of thymidine. These cultures were harvested and quantitated as follows: Medium was removed and skin sections washed 2X with ice cold PBS. Ice cold 50% trichloroacetic acid (TCA) was added and cultures
5 incubated at room temperature for 30 mins. TCA was removed and sections washed 2X in ice cold deionized water, and 2X in ice cold 95% ethanol. Sections were dried at room temperature for 3 hours, then individually weighed to obtain mg/ skin section. Sections were placed in scintillation fluid and counted, to quantitate cpm of thymidine incorporated per section,
10 and the cpm/ mg tissue calculated from the weight of each section. For each of four mice, a minimum of 12 sections per time point were used. For each mouse, cpm/mg tissue incorporated by untreated skin (medium alone) was control. The % inhibition in enzyme treated skin was calculated using the control value for each mouse.

15 There was no inhibition of fibroblast proliferation on day 1 or day 4. However, a decrease in proliferation was observed after skin sections were treated with 1 and 10 IU/ml of chondroitinase B for 8 days. As shown in Figure 7, cell proliferation was inhibited by 35% and 48% respectively, in skin treated with 1.0 and 10 IU/ml of chondroitinase B. The effect in skin
20 treated with 10 IU/ml was significant at a level of $p=.002$, determined by ANOVA and Dunnet's group comparisons.

The effect of Chondroitinase B on skin was also evaluated in stained sections. On the day cultures were initiated (day 0) and days 4 and 8, untreated or enzyme-treated sections were fixed in 10% buffered formalin,
25 embedded in paraffin, sectioned and stained with hematoxylin and eosin for histological examination. Assessment of sectioned skin was based on three sections/ treatment/ mouse/ time point. For each section, a calibrated ocular micrometer was used to measure the thickness of the stratum corneum, the epidermis and the dermis. Three measurements of each layer were taken in
30 different areas of the same section.

Based on the histological evaluation, there were no significant changes in the thickness of the stratum corneum or the epidermis. There was

however a significant reduction in the thickness of the dermis, the skin layer containing dermal fibroblasts in cultures treated with chondroitinase B. As shown in Figure 8, the thickness of the dermis in skin sections treated with 1.0 and 10 IU/ml of chondroitinase B was 36 and 40% less than that of controls. The reduced thickness of the dermal layer reflects a reduction in the number of fibroblasts, and is in agreement with the decreased cell proliferation, as measured by uptake of tritiated thymidine.

Example 7: Inhibition of the expression of procollagen and TGF β in a mouse model of pulmonary fibrosis.

The effects of Chondroitinase B on the synthesis of type I collagen, and the collagen-promoting cytokine, TGF β , were examined in a mouse model of pulmonary fibrosis. In this model, fibrosis is induced in the lungs of mice, by the intratracheal injection of the antineoplastic drug Bleomoxane®(bleomycin sulfate). Bleomycin-induced fibrosis is very similar to human idiopathic pulmonary fibrosis, as documented by studies of the changes in morphology, biochemistry and mRNA in both mice and humans with this disease. (Phan,S.H. Fibrotic mechanisms in lung disease. In : Immunology of Inflammation, edited by P.A. Ward, New York: Elsevier, 1983, pp121-162; Zhang et. al. (1994) Lab. Invest. 70: 192-202; Phan and Kunkel (1992) Exper. Lung Res. 18:29-43.)

Mice used in these experiments were CBA/J, which were 8 weeks old and approximately 25g. Mice were divided into 3 treatment groups of 6 mice per group. Mice in each group were treated as follows:

	GROUPS		
DAY	1	2	3
0	i.t. saline	i.t. bleomycin 0.025 U in saline	i.t. bleomycin 0.025 U in saline
3,5,7,9,11	i.p. saline	i.p. saline	i.p. Chondroitinase B 20IU in saline

i.t. – intratracheal administration; i.p. = intraperitoneal injection

On Day 21, all mice were killed by lethal injection of sodium pentobarbital. Lungs were flushed with saline to remove blood, and mRNA

extracted, and the expression of procollagen I, and TGF β were assessed as described by Phan and Kunkel (1992; Exper. Lung Res. 18:29-43). The amount of mRNA contained in lungs of mice from the different treatment groups was quantified from densitometry readings from films following

5 Northern blot analysis. The lungs of mice treated with bleomycin followed by Chondroitinase B, contained significantly less mRNA for both procollagen type I and for the collagen synthesis promoting cytokine, TGF β . These results indicate that Chondroitinase B was effective in inhibiting the expression of mRNA for two key proteins which have shown to be greatly

10 increased in fibrotic lungs.

We claim:

1. A method to modulate fibrous tissue formation comprising administering to an individual in need of treatment thereof an effective amount of a dermatan sulfate or chondroitin sulfate degrading enzyme.
2. The method of claim 1 wherein the enzyme is selected from the group consisting of bacterial dermatan or chondroitin sulfate degrading enzyme and is selected from the group consisting of chondroitinase AC from *Flavobacterium heparinum*, chondroitinase B from *Flavobacterium heparinum*, chondroitin sulfate degrading enzymes from *Bacteroides* species, chondroitin sulfate degrading enzymes from *Proteus vulgaris*, chondroitin sulfate degrading enzymes from *Micrococcus*, chondroitin sulfate degrading enzymes from *Vibrio* species, chondroitin sulfate degrading enzymes from *Arthrobacter aureescens*, arylsulfatase B, N-acetylgalactosamine-6-sulfatase and iduronate sulfatase from mammalian cells, these enzymes expressed from recombinant nucleotide sequences in bacteria and combinations thereof.
3. The method of claim 1 wherein the enzyme is a mammalian enzyme.
4. The method of claim 1 wherein the enzyme is a bacterial enzyme.
5. The method of claim 4 wherein the chondroitinase is chondroitinase B.
6. The method of claim 1 wherein the individual has a skin disorder.
7. The method of claim 6 wherein the skin disorder is scleroderma or psoriasis.
8. The method of claim 1 wherein the individual has keloid scarring or is at risk of keloid scarring, or has pulmonary fibrosis.
9. The method of claim 1 wherein the enzyme is administered systemically.
10. The method of claim 1 wherein the enzyme is administered topically or locally at or adjacent to a site in need of treatment.

11. The method of claim 1 wherein the enzyme is administered in a controlled and/or sustained release formulation.

12. A formulation for administration to an individual in need of treatment thereof for a disorder involving organ fibrosis, the formulation comprising an effective amount of a dermatan or chondroitin sulfate degrading enzyme to inhibit fibrosis, wherein the dosage is different than the amount effective for wound healing, and a pharmaceutically acceptable carrier.

13. The formulation of claim 12 wherein the enzyme is selected from the group consisting of bacterial chondroitin sulfate degrading enzyme and is selected from the group consisting of chondroitinase AC from *Flavobacterium heparinum*, chondroitinase B from *Flavobacterium heparinum*, chondroitin sulfate degrading enzymes from *Bacteroides* species, chondroitin sulfate degrading enzymes from *Proteus vulgaris*, chondroitin sulfate degrading enzymes from *Micrococcus*, chondroitin sulfate degrading enzymes from *Vibrio* species, chondroitin sulfate degrading enzymes from *Arthrobacter aureus*, these enzymes expressed from recombinant nucleotide sequences in bacteria and combinations thereof.

14. The formulation of claim 12 wherein the enzyme is a mammalian enzyme.

15. The formulation of claim 12 wherein the enzyme is a bacterial chondroitinase.

16. The formulation of claim 15 wherein the chondroitinase is chondroitinase B.

17. The formulation of claim 12 wherein the enzyme is in a controlled, sustained release formulation.

18. The formulation of claim 12 in a dosage effective to collagen synthesis.

19. The formulation of claim 12 in an effective aerosol formulation for delivery to the lungs.

1/5

Figure 1





Figure 2



2/5

Figure 3 bFGF binding to dermal fibroblasts





Figure 4



3/5

Figure 5




Figure 6







Figure 7 Cellular Proliferation in Flaky Skin mouse organ cultures**Figure 8 Dermal thickness in Flaky Skin mouse organ cultures**

Figure 9 Procollagen and TGF β Expression in Mouse Lungs



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number
WO 01/39795 A3

(51) International Patent Classification⁷: A61K 38/46, 38/51, A61P 17/00, 43/00

(21) International Application Number: PCT/US00/32399

(22) International Filing Date:
28 November 2000 (28.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/168,518 2 December 1999 (02.12.1999) US

(71) Applicant: IBEX TECHNOLOGIES, INC. [CA/US]; 5
Great Valley Parkway, Suite 300, Malvern, PA 19355 (US).

(72) Inventors: DENHOLM, Elizabeth, M.; 2 Victoria Avenue, Pointe Claire, Quebec H9S 4S3 (CA). CAUCHON, Elizabeth; 83 rue des Pins, Ile Perrot, Quebec J7V 8L6 (CA). SILVER, Paul, J.; 154 Barton Drive, Spring City, PA 19475-3418 (US).

(74) Agents: PABST, Patrea, L. et al.; Holland & Knight LLP, Suite 2000, One Atlantic Center, 201 West Peachtree Street, Atlanta, GA 30309-3400 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
27 December 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ATTENUATION OF FIBROBLAST PROLIFERATION

(57) Abstract: Highly purified and specific glycosaminoglycan degrading enzymes, chondroitinase B and chondroitinase AC, are used to treat fibroproliferative diseases. The enzymatic removal of chondroitin sulfate B (dermatan sulfate), and to a lesser extent, chondroitin sulfate A or C, from cell surfaces effectively decreases growth factor receptors on the cells and thereby decreases the cell proliferative response to such growth factors. In addition, removal of chondroitin sulfates reduces secretion of collagen, one of the major extracellular matrix components. Through the combined inhibition of fibroblast proliferation and collagen synthesis, treatment with chondroitinase B or chondroitinase AC decreases the size of fibrous tissue found in psoriasis, scleroderma, keloids, pulmonary fibrosis and surgical adhesions.



WO 01/39795 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/32399

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/46 A61K38/51 A61P17/00 A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Data, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; DONATI L ET AL: "Treatment of hypertrophic and keloid cicatrices with thiomucase!. Il trattamento delle cicatrici ipertrofiche e cheloidee mediante thiomucase." retrieved from STN Database accession no. 76196588 XP002169931 abstract & MINERVA CHIRURGICA, (1975 MAR 31) 30 (6) 326-33. ,</p> <p style="text-align: center;">--- -/-</p>	1,6,8-11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *S* document member of the same patent family

Date of the actual completion of the international search

18 June 2001

Date of mailing of the international search report

28/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stein, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/32399

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 695 752 A (IMAI YASUYUKI ET AL) 9 December 1997 (1997-12-09) column 6, line 6 -column 7, line 5 column 13, line 17 -column 14, line 4 column 15, line 12 -column 16, line 62 ---	1-7,9-11
X	WO 98 46258 A (BETH ISRAEL HOSPITAL) 22 October 1998 (1998-10-22) the whole document ---	1-5,8-19
X	WO 99 48478 A (YACOBY ZEEVI ORON ;FRIEDMAN MARK M (IL); INSIGHT STRATEGY & MARKET) 30 September 1999 (1999-09-30) the whole document ---	1-5,8-19
X	WO 95 13091 A (INT TECH MANAGEMENT ASS ;RATCLIFFE ANTHONY (US); UNIV COLUMBIA (US) 18 May 1995 (1995-05-18) page 7, line 22 -page 8, line 4 page 8, line 31 -page 9, line 17 page 12, line 16 -page 14, line 8 page 17, line 26 - line 27 claims 1,16,17 ---	1-4, 9-15,17, 18
A	DENHOLM ELIZABETH M: "Inhibition of fibroblast proliferation by chondroitinase AC(CAC) and chondroitinase B(CB)." FASEB JOURNAL, vol. 12, no. 5, 20 March 1998 (1998-03-20), page A948 XP002169930 Annual Meeting of the Professional Research Scientists on Experimental Biology 98, Part II;San Francisco, California, USA; April 18-22, 1998 ISSN: 0892-6638 the whole document ---	1-19
T	DENHOLM ELIZABETH M ET AL: "Inhibition of human dermal fibroblast proliferation by removal of dermatan sulfate." EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 400, no. 2-3, 2000, pages 145-153, XP001009717 ISSN: 0014-2999 the whole document -----	1-19

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 1,3,4,6-12,14,17-19 all partially

Present claims 1,3,4,6-12,14,17-19 relate to an enzyme defined by reference to a desirable property, namely its dermatan sulfate or chondroitin sulfate degrading activity. However these claims do not contain any structural or essential characteristics of the enzyme. The claims cover all enzymes having this property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such enzymes. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the enzyme by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the enzymes mentioned in the description at page 6 line 18- page 8 line 17 and in claims 2,5,13,15 and 16 of the application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

Intel. Application No

PCT/US 00/32399

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5695752	A	09-12-1997	US 5925349 A	20-07-1999
			AU 700369 B	07-01-1999
			AU 2120995 A	03-10-1995
			CA 2185324 A	21-09-1995
			EP 0750511 A	02-01-1997
			JP 10500939 T	27-01-1998
			WO 9524920 A	21-09-1995
			AU 4859793 A	12-04-1994
			WO 9406442 A	31-03-1994
			US 5580862 A	03-12-1996
			AU 1255695 A	06-06-1995
			WO 9513819 A	26-05-1995
			US 5489578 A	06-02-1996
			US 5783693 A	21-07-1998
WO 9846258	A	22-10-1998	AU 6897198 A	11-11-1998
			US 6200564 B	13-03-2001
WO 9948478	A	30-09-1999	US 6153187 A	28-11-2000
			AU 3107799 A	18-10-1999
WO 9513091	A	18-05-1995	AU 1176595 A	29-05-1995
			US 5916557 A	29-06-1999

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number
WO 01/039795 A3

(51) International Patent Classification⁷: A61K 38/46,
38/51, A61P 17/00, 43/00

(21) International Application Number: PCT/US00/32399

(22) International Filing Date:
28 November 2000 (28.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/168,518 2 December 1999 (02.12.1999) US

(71) Applicant: IBEX TECHNOLOGIES, INC. [CA/US]; 5
Great Valley Parkway, Suite 300, Malvern, PA 19355 (US).

(72) Inventors: DENHOLM, Elizabeth, M.; 2 Victoria Avenue, Pointe Claire, Quebec H9S 4S3 (CA). CAUCHON, Elizabeth; 83 rue des Pins, Ile Perrot, Quebec J7V 8L6 (CA). SILVER, Paul, J.; 154 Barton Drive, Spring City, PA 19475-3418 (US).

(74) Agents: PABST, Patrea, L. et al.; Holland & Knight LLP, Suite 2000, One Atlantic Center, 201 West Peachtree Street, Atlanta, GA 30309-3400 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(88) Date of publication of the international search report:
27 December 2001

(48) Date of publication of this corrected version:
25 July 2002

(15) Information about Correction:
see PCT Gazette No. 30/2002 of 25 July 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ATTENUATION OF FIBROBLAST PROLIFERATION

(57) Abstract: Highly purified and specific glycosaminoglycan degrading enzymes, chondroitinase B and chondroitinase AC, are used to treat fibroproliferative diseases. The enzymatic removal of chondroitin sulfate B (dermatan sulfate), and to a lesser extent, chondroitin sulfate A or C, from cell surfaces effectively decreases growth factor receptors on the cells and thereby decreases the cell proliferative response to such growth factors. In addition, removal of chondroitin sulfates reduces secretion of collagen, one of the major extracellular matrix components. Through the combined inhibition of fibroblast proliferation and collagen synthesis, treatment with chondroitinase B or chondroitinase AC decreases the size of fibrous tissue found in psoriasis, scleroderma, keloids, pulmonary fibrosis and surgical adhesions.

WO 01/039795 A3



ATTENUATION OF FIBROBLAST PROLIFERATION

Background of the Invention

The present invention is a method and composition using
5 chondroitinase B and chondroitinase AC, glycosaminoglycan degrading
enzymes, to inhibit the formation of fibrotic tissue.

Proteoglycans on the cell surface and in the extracellular matrix
contain variable glycosaminoglycan chains, which include heparan sulfate
and chondroitin sulfates A, B, or C. While some proteoglycans contain only
10 one type of glycosaminoglycan, others contain a mixture of heparan and
chondroitin sulfates (Jackson et. al., *Physiol. Rev.* 71:481-530,1991).
Extracellular proteoglycans form a structural framework for cells and tissues,
and together with cell-associated proteoglycans, have major functions in
regulating cell adhesion, migration, and proliferation. The functions of
15 proteoglycans and their component parts have been extensively studied, with
much of the emphasis on the roles of heparin and heparan sulfate on cell
metabolism (Kjellen, L., and Lindahl, U. (1991) *Ann. Rev. Biochem.*
60:443-475; Vlodavsky, et al. (1995) *Thrombosis Haemostasis* 74:534-540;
Yayon, et al. (1991) *Cell* 64:841-848)). Much less is known about the
20 biological activities of proteoglycans containing chondroitin sulfate
glycosaminoglycans, and in particular, their effects on cell proliferation.

Two inhibitors of glycosaminoglycan synthesis, chlorate and beta-
xyloside, have been used to examine the relative contributions of heparan
and chondroitin sulfate proteoglycans to control of the cell cycle (Keller, et
25 al. (1989) *Biochem.* 28:8100-8107; Miao, et al. (1995) *J. Cell. Biochem.*
57:713-184; Schwartz, N.B. (1977) *J. Biol. Chem.* 252:6316-6321).
However both of these compounds inhibit the expression of all types of
sulfated glycosaminoglycans. There are currently no inhibitors which can
selectively block the synthesis or expression of chondroitin sulfate A, B or C.
30 However, specific glycosaminoglycan lyases which can remove either
heparan or chondroitin sulfates A, B or C from cells are available.
Chondroitinases have been isolated from several bacterial species:

Flavobacterium heparinum, *Aeromonas sp.*, *Proteus vulgaris*,
Aureobacterium sp. and *Bacillus thetaiota micron* (Linhardt, et al. (1986) Appl.
Biochem. Biotech. 12:135-175; Linn, et al. (1983) J. Bacteriol. 156:859-866;
Michellacci, et al. (1987) Biochim. Biophys. Acta. 923:291-301; and Sato, et
5 al. (1986) Agric. Biol. Chem. 50:1057-1059).

Most studies examining the activities of chondroitin sulfate
proteoglycans (Lyon, et al. (1998) J. Biol. Chem. 273:271-278; Maeda, et al.
(1996) J. Biol. Chem. 271:21446-21452; Milev, et al. (1998) J. Biol. Chem.
273:21439-21442; Rapraeger, 1989, and Schmidt, et al. (1992) J. Biol.
10 Chem. 267:19242-19247) have utilized one such enzyme, chondroitinase
ABC (from *Proteus vulgaris*, Yamagata, et al. (1968) J. Biol. Chem.
243:1523-1535) which degrades all chondroitin sulfates (chondroitin sulfate
A, chondroitin sulfate C and chondroitin sulfate B). Since chondroitinase
ABC acts on more than one type of chondroitin sulfate, it is not possible to
15 determine the biological activity of the individual types of chondroitin
sulfates using this enzyme.

Evidence for a role of chondroitin sulfate A or B or C proteoglycans
in cell proliferation includes data which shows upregulation during rapid cell
proliferation, as occurs in wound healing (Penc and Gallo (1998) J. Biol.
20 Chem. 273:28116-28121; Yeo, et al. (1991) Amer. J. Pathol. 138:1437-1450)
and down regulation in quiescent cells (Tao et. al. (1997) Atherosclerosis
135:171-179). Such studies suggest that there may be a relationship between
the secretion and expression of cell surface chondroitin sulfate proteoglycans
and cell proliferation.

25 Recent studies in wound healing have found that chondroitin sulfate
B proteoglycans are present in high concentration in the fluid of healing
wounds, and that addition of these proteoglycans to a wounded area may
promote healing (Penc and Gallo, 1998). Although the mechanism of action
of the chondroitin sulfate B in wound healing is unknown, it is possible that
30 these proteoglycans may directly or indirectly affect cell proliferation.

It is therefore an object of the present invention to provide a method and compositions for treatment of conditions associated with abnormal formation of fibrous tissue, through modification of proteoglycans.

5 It is another object of the present invention to provide a method and compositions to modulate collagen synthesis, decrease TGFbeta production, decrease fibroblast proliferation or migration, release chondroitin sulfate proteoglycans from cells, and decrease growth factor binding sites on fibroblasts.

10 It is a further object of the present invention to provide a method and compositions to treat disorders which involve hyperproliferation of fibroblasts such as scleroderma, psoriasis, keloids, pulmonary fibrosis and surgical adhesions.

Summary of the Invention

15 Highly purified and specific glycosaminoglycan degrading enzymes, chondroitinase B and chondroitinase AC, are used to treat fibroproliferative diseases. The enzymatic removal of chondroitin sulfate B, and to a lesser extent, chondroitin sulfate A or C, from cell surfaces effectively decreases growth factor receptors on the cells and thereby decreases the cell proliferative response to such growth factors. In addition, removal of
20 chondroitin sulfates reduces secretion of collagen, one of the major extracellular matrix components. Through the combined inhibition of fibroblast proliferation and collagen synthesis, treatment with chondroitinase B or chondroitinase AC decreases the size of fibrous tissue found in psoriasis, scleroderma, keloids and surgical adhesions.

25

Brief Description of the Drawings

Figures 1A and 1B are graphs of the release of sulfated glycosaminoglycan from fibroblasts, following treatment with *Flavobacterium heparinum* derived Chondroitinase B, as a function of time
30 (Figure 1A) or dose (Figure 1B). Figure 1A shows the release of ³⁵S-glycosaminoglycans after treatment with 1.0 IU/ml of enzyme for the indicated time (min). Figure 1B shows the release of ³⁵S-

glycosaminoglycans after treatment with the indicated concentration of enzyme for one hr. Data are the cpm/well of ^{35}S -glycosaminoglycans released by enzyme treatment (cpm enzyme treated cells minus cpm cells treated with medium alone), from a representative of two such experiments performed in triplicate. Mean cpm released by medium alone was $8,160 \pm 599$.

Figure 2 is a graph of the time and dose dependent release of sulfated glycosaminoglycans from fibroblasts following treatment with *Flavobacterium heparinum* derived Chondroitinase AC. Solid bars represent release after a one hr treatment, and open bars are release after a 2 hr treatment. Data are the cpm/well of ^{35}S -glycosaminoglycans released by enzyme treatment (cpm enzyme treated cells minus cpm cells treated with medium alone), from a representative of two such experiments performed in triplicate. Mean cpm released by medium alone was $4,028 \pm 54$.

Figures 3A and 3B are graphs of the binding of ^{125}I -bFGF to fibroblast glycosaminoglycans (GAGs, Figure 3A) and bFGF receptors (Figure 3B) following treatment with *Flavobacterium heparinum* derived Chondroitinase B. Total (triangles), nonspecific (o) and specific (•) binding are shown. Data is from a representative of five such experiments performed in duplicate.

Figure 4 is a graph of the Scatchard analysis of bFGF bound to receptors of fibroblasts treated with medium (control, •) or 1.0 IU/ml of *Flavobacterium heparinum* derived chondroitinase B (o). Data are from a representative of five such experiments performed in duplicate.

Figures 5A and 5B are graphs of the dose dependent effects of *Flavobacterium heparinum* derived chondroitinase B (Figure 5A) and chondroitinase AC (Figure 5B) on fibroblast proliferation in response to 10% fetal bovine serum (serum) (•) or 100 pg/ml bFGF (o). Data are the % inhibition of proliferation for cells treated with chondroitinase B compared to cells treated with medium alone. Each point is the mean \pm sem of four experiments performed in triplicate.

Figure 6 is a graph of the collagen content of the extracellular matrix of fibroblasts treated with 0 to 10 IU/ml of *Flavobacterium heparinum* derived chondroitinase B, in the absence (cross hatched) or presence (black) of 25 ng/ml TGF-beta.

5 Figure 7 is a graph of the inhibition of cell proliferation in mouse skin cultures treated for 8 days with 0.1 to 10 IU/ml of *Flavobacterium heparinum* derived chondroitinase B. Proliferation was assessed by the incorporation of 3H-thymidine into skin sections following a 24 hr exposure. Data are expressed as % inhibition when compared to controls (no enzyme).
10 Each bar represents the mean \pm sem of 36 skin sections, taken from 3 mice. The * indicates inhibition was statistically significant with $p < 0.05$.

 Figure 8 is a graph of the decrease in dermal thickness in mouse skin cultures treated for 8 days with 0.1 to 10 IU/ml of *Flavobacterium heparinum* derived chondroitinase B. Data are expressed as % decrease
15 compared to controls (no enzyme). Each bar represents the mean \pm sem of measurements taken from 18 skin sections, from 3 mice. The * indicates that inhibition (decrease in thickness) was statistically significant with $p < 0.05$.

 Figures 9a and 9b are graphs of the inhibition of the expression of mRNA for procollagen I (Figure 9a) and TGF β (Figure 9b) in the lungs of
20 mice treated with Chondroitinase B. Treatment groups indicate the route and substance injected into the trachea/ or peritoneal cavity respectively. ChB is 25 IU of enzyme per injection; BLM is one injection of 0.025 units of bleomycin sulfate; and SAL indicates the injection of equal volumes of saline. Data are expressed as integration units ($\times 10^3$) as determined by densitometry readings
25 of Northern blot films. Each bar represents the mean \pm sem of 6 mice. The * indicates the decrease in mRNA expression was significantly less than that found in mice given BLM/SAL.

Detailed Description of the Invention

30 Glycosaminoglycans, including chondroitin sulfates A, B or C, and heparan sulfate, are the sulfated polysaccharide components of proteoglycans located on cell surfaces, where they act as co-receptors for cytokines and

growth factors and in the extracellular space where they form the structure of the extracellular matrix and serve as a supporting and organizational structure of tissues and organs.

Two ultra-purified enzymes from *Flavobacterium heparinum*,
5 chondroitinase B whose sole substrate is chondroitin sulfate B, and
chondroitinase AC whose substrates are chondroitin sulfate A and C, have
made it possible to distinguish between the activities of the different
chondroitin sulfates and to directly assess their influence on human skin
fibroblast proliferation. Starting from the premise that chondroitin sulfate
10 proteoglycans promote cell proliferation, it has now been demonstrated that
removal of chondroitin sulfate B, and, to a lesser extent, chondroitin sulfate
A or C, inhibits cell proliferation.

The method for inhibiting events in the fibrotic process by the use of
a highly purified glycosaminoglycan degrading enzyme, preferably from
15 *Flavobacterium heparinum*, is demonstrated in the examples.

Enzyme Formulations

Enzymes

The chondroitinase B and chondroitinase AC described in the
examples are glycosaminoglycan degrading enzymes from *Flavobacterium*
20 *heparinum*. Both enzymes modulate the interactions involved in cell
proliferation and extracellular matrix synthesis by i) releasing chondroitin
sulfate proteoglycans from cells; ii) decreasing growth factor binding sites on
cells; iii) decreasing fibroblast proliferation ; iv) decreasing TGFbeta
production, and v) decreasing collagen synthesis and thereby decreasing
25 fibrous tissue formation.

Glycosaminoglycans are unbranched polysaccharides consisting of
alternating hexosamine and hexuronic residues which carry sulfate groups in
different positions. This class of molecules can be divided into three families
according to the composition of the disaccharide backbone. These are:
30 heparin/heparan sulfate [HexA-GlcNAc(SO₄)]; chondroitin sulfate [HexA-
GalNAc]; and keratan sulfate [Gal-GlcNAc].

Representative glycosaminoglycan degrading enzymes include heparinase 1 from *Flavobacterium heparinum*, heparinase 2 from *Flavobacterium heparinum*, heparinase 3 from *Flavobacterium heparinum*, chondroitinase AC from *Flavobacterium heparinum*, and chondroitinase B from *Flavobacterium heparinum*, heparinase from *Bacteroides* strains, heparinase from *Flavobacterium* Hp206, heparinase from *Cytophagia* species, chondroitin sulfate degrading enzymes from *Bacteroides* species, chondroitin sulfate degrading enzymes from *Proteus vulgaris*, chondroitin sulfate degrading enzymes from *Micrococcus*, chondroitin sulfate degrading enzymes from *Vibrio* species, chondroitin sulfate degrading enzymes from *Arthrobacter aurescens*, these enzymes expressed from recombinant nucleotide sequences in bacteria and combinations thereof. Other enzymes which degrade glycosaminoglycans are present in mammalian cells and include heparanases, arylsulfatase B, N-acetylgalactosamine-6-sulfatase, and iduronate sulfatase.

The chondroitin sulfate family includes seven sub-types designated unsulfated chondroitin sulfate, oversulfated chondroitin sulfate and chondroitin sulfates A-E which vary in the number and position of their sulfate functional groups. Additionally, chondroitin sulfate B, also referred to as dermatan sulfate, differs in that iduronic acid is the predominant residue in the alternative hexuronic acid position.

Chondroitin sulfates A, B and C are the predominant forms found in mammals and may be involved in the modulation of various biological activities including cell differentiation, adhesion, enzymatic pathways and hormone interactions. The presence of chondroitin sulfate proteoglycans is elevated in the later stages of cell growth in response to tissue and vessel damage, as reported by Yeo, et al., *Am. J. Pathol.* 138:1437-1450, 1991, Richardson and Hatton, *Exp. Mol. Pathol.* 58:77-95, 1993 and Forrester, et al., *J. Am. Coll. Cardiol.* 17:758-769, 1991. Chondroitin sulfates also have been associated with events involved in the progression of vascular disease and lipoprotein uptake as described by Tabas, et al., *J. Biol. Chem.*, 268(27):20419-20432, 1993.

Chondroitinases have been isolated from several bacterial species:

Flavobacterium heparinum, *Aeromonas sp.*, *Proteus vulgaris*,
Aureobacterium sp. and *Bacillus thetaiotamicron* (Linhardt et. al., 1986; Linn
et. al., J. Bacteriol. 156:859-866, 1983; Michelacci et. al., Biochim. Biophys.
5 Acta. 923:291-201, 1987; and Sato et. al., Agric. Biol. Chem. 50:1057-1059,
1986). PCT/US95/08560 "*Chondroitin Lyase Enzymes*" by Ibex
Technologies R and D, Inc., et al. describes methods for purification of
naturally produced chondroitinases, especially separation of chondroitinase
AC from chondroitinase B, as well as expression and purification of
10 recombinant chondroitinases. Mammalian enzymes which degrade
chondroitin sulfates include arylsulfatase B, N-acetylgalactosamine-6-
sulfatase, and iduronate sulfatase.

Those enzymes useful in the methods and compositions described
herein will cleave proteoglycans on the surfaces of cells, in particular
15 fibroblasts, most preferably those which serve as receptors involved in cell
proliferation and/or migration and/or gene expression, particularly of
collagen.

Formulations

For topical application, the glycosaminoglycan degrading enzyme is
20 combined with a carrier so that an effective dosage is delivered, based on the
desired activity, at the site of application. For topical application, several
ointments and cremes are currently used for other therapeutics agents; any
one of which can be used for the application of chondroitinase B or AC. The
topical composition can be applied to the skin for treatment of diseases such
25 as psoriasis. The carrier may be in the form of an ointment, cream, gel,
paste, foam, aerosol, suppository, pad or gelled stick. For topical application,
several ointments and cremes are currently used for other therapeutics
agents; any one of which can be used for the application of chondroitinase B
or AC. A topical composition consists of an effective amount of
30 glycosaminoglycan degrading enzyme in a pharmaceutically acceptable
excipient such as buffered saline, mineral oil, vegetable oils such as corn or

arachis oil, petroleum jelly, Miglyol 182, alcohol solutions, or liposomes or liposome-like products.

Compositions for local or systemic administration will generally include an inert diluent. For example, for injection, chondroitinase B or AC
5 can be prepared in physiological balanced buffer solutions. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents
10 such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of
15 glass or plastic.

For directed internal topical applications, the composition may be in the form of tablets or capsules, which can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as
20 starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; or a glidant such as colloidal silicon dioxide. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials
25 which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents. Any of these formulations may also include preservatives, antioxidants, antibiotics, immunosuppressants, and other biologically or pharmaceutically effective agents which do not exert a detrimental effect on the glycosaminoglycan degrading enzyme or cells.

30 The glycosaminoglycan degrading enzyme can also be administered in combination with a biocompatible polymeric implant which releases the glycosaminoglycan degrading enzyme over a controlled period of time at a

selected site. Examples of preferred biodegradable polymeric materials include polyanhydrides, polyorthoesters, polyglycolic acid, polyesters such as polylactic acid, polyglycolic acid, polyethylene vinyl acetate, and copolymers and blends thereof. Examples of preferred non-biodegradable polymeric materials include ethylene vinyl acetate copolymers.

Other Therapeutic Agents which can be Administered in Combination

The glycosaminoglycan degrading enzymes can be administered alone or in combination with other treatments. For example, the enzymes can be administered with antibiotics, antibodies to cytokines and chemokines (such as TNFalpha, TGFbeta, Il-1, Il-6), and anti-inflammatory such as cortisone.

Other combinations will be apparent to those skilled in the art.

Methods of Treatment

Excessive cell proliferation is characteristic of chronic diseases such as psoriasis, scleroderma and pulmonary fibrosis. Each of these diseases represents a complex interaction of the individual cell types composing the involved organ. In general terms these diseases are characterized by uncontrolled cell proliferation and the deposition of excess collagen and glycosaminoglycans (Liu and Connolly (1998) Sem. Cutaneous Med. and Surg. 17:3-11; and Phan, S.H. Fibrotic mechanisms in lung disease. In: Immunology of Inflammation, edited by P.A. Ward, New York: Elsevier, 1983, pp121-162). Although collagen is considered to be the major component of fibrotic scar tissue, recent work has indicated that sulfated glycosaminoglycans may be crucial to the process of collagen deposition and tissue remodeling which occurs in such diseases (Bensadoun, et al. (1996) Amer. J. Respir. Crit. Care Med. 154:1819-1828).

A key cell in all these diseases is the fibroblast. Fibroblast proliferation and matrix secretion are responsible for much of the increase in tissue thickness and density. Fibroblasts make a major contribution to the excessive scar tissue in post-surgical adhesions, and in keloids which form after injuries such as burns. The mechanisms controlling fibroblast proliferation and secretion of collagen and glycosaminoglycans are complex. substances

which activate fibroblasts include cytokines, chemokines and growth factors, produced by other cells, and by fibroblasts themselves. One such cytokine is TGF-beta, considered to be a key controller of collagen synthesis. TGF-beta is secreted by fibroblasts and can feedback to enhance its own secretion, increasing both fibroblast matrix production and proliferation. TGF-beta activities are mediated through the interaction of specific receptors, sulfated glycosaminoglycans associated with them, and with other matrix proteins (Segarini, et al. (1989) Molecular Endocrinol. 3:261-272).

As demonstrated by the examples, the glycosaminoglycan degrading enzyme is administered to the site to be treated in a dosage effective to modulate collagen synthesis, fibroblast proliferation or migration, release chondroitin sulfate proteoglycans from cells; decrease growth factor binding sites on cells, and thereby decrease fibrous tissue formation, as appropriate for the specific application. Application is either topical, localized, sub-dermal or systemic.

Chondroitinase B or chondroitinase AC can be applied topically, for example, to lesions of scleroderma, psoriasis and keloids; or injected sub-dermally (locally), for example, into keloids and surgical adhesions. These chondroitinases may also be used systemically to treat pulmonary fibrosis, either via intravenous injection or via aerosol administration directly into the lungs.

Examples

The present invention will be further understood by reference to the following non-limiting examples.

Example 1: Enzyme substrate specificity.

Chondroitinase B (no EC number) and chondroitinase AC (EC 4.2.2.5) are recombinant proteins expressed in *Flavobacterium heparinum* (PCT/US95/08560 "Chondroitin Lyase Enzymes"). Specific activity and substrate specificity were determined for each enzyme, using a kinetic spectrophotometric assay, performed essentially as described in PCT/US95/0856. In these assays, enzyme concentrations were 0.25 IU/ml and substrate concentrations were 0.5 mg/ml (chondroitin sulfate B and

chondroitin sulfate AC) or 0.75 mg/ml (heparan sulfate). The specific activities of the enzymes were: 97 IU/mg for Chondroitinase B and 221 IU/mg for chondroitinase AC.

The substrate specificity of ultra-purified Chondroitinase B and AC were determined by testing the ability of the enzymes to degrade chondroitin sulfate B, chondroitin sulfate A, chondroitin sulfate C, and heparan sulfate. As shown in Table 1, both enzymes were active towards the corresponding sulfated glycosaminoglycan, with 0.2% or less activity against any of the other glycosaminoglycans. These results confirm the substrate specificity of the purified Chondroitinase B and Chondroitinase AC used in this application.

Table 1: Comparative Enzymatic Activities Against Glycosaminoglycans

<u>Enzyme</u>	<u>Substrate</u>			
	<u>CSB</u>	<u>CSA</u>	<u>CSC</u>	<u>HS</u>
<u>Chondroitinase B</u>				
IU/ml	399	0.04	0.03	0.92
(relative activity)	(100)	(0.01)	(0.01)	(0.23)
<u>Chondroitinase AC</u>				
IU/ml	0.604	1238	735	2.2
(relative activity)	(0.05)	(100)	(59)	(0.18)

Enzyme activities are shown as IU/ml with each substrate, and as the relative activity towards each substrate. Relative activity was determined after assigning 100% for the preferred substrate (CSB for chondroitinase B, CSA for chondroitinase AC. CSB=chondroitin sulfate B; CSA=chondroitin sulfate A; CSC=chondroitin sulfate C; HS=heparan sulfate. Substrate concentrations were 500 mcg/ml (CSB, CSA, CSC) or 750 mcg/ml (HS).

Example 2: Removal of glycosaminoglycans from cells

The effectiveness of the chondroitinases B and AC in removing sulfated glycosaminoglycans from cells was examined using cells with glycosaminoglycans labeled by incubation with ³⁵S. Fibroblasts were plated

at a density of 6×10^4 cells/well in 24 well plates, in DMEM with 10% serum. After 24 hrs, medium was changed to Fisher's medium containing 10% serum and 25 microCi/ml of $\text{Na}_2^{35}\text{SO}_4$, and incubation continued for 2.5 days. The medium was removed and cells rinsed 2X with DMEM then
5 treated with Chondroitinase B or AC as indicated. Medium was removed and radioactivity determined. The release of sulfated glycosaminoglycans from cells by enzyme was expressed as cpm/well of chondroitinase-treated cells minus cpm/well of untreated cells.

Cells were exposed to 1.0 IU/ml of Chondroitinase B, at 37°C for
10 variable lengths of time. As shown in Figure 1A, maximal release of sulfated GAGs by chondroitinase B was achieved following an 1 hour exposure to enzyme. Further experiments were done, in which fibroblasts were treated for 1 hour with varying concentrations of Chondroitinase B. Figure 1B illustrates that the release of sulfated glycosaminoglycans from
15 fibroblasts was also dependent on the concentration of chondroitinase B used.

The release of sulfated GAGs by chondroitinase AC was examined by treating fibroblasts for 1 or 2 hrs with 0.1 and 1.0 IU/ml of enzyme. As shown in Figure 2, the release of sulfated GAGs by chondroitinase AC was
20 both time and dose dependent. Maximal release was achieved after a 2 hr treatment with 1.0 IU/ml of enzyme.

Example 3: Effects on bFGF binding

Iodinated bFGF was obtained from Dupont NEN, specific activity greater than 1200 Ci/mmol. Fibroblasts were plated in 48 well dishes and
25 grown to confluence. Prior to binding assays, cells were treated with medium or enzyme as indicated for proliferation assays. Following enzyme treatments, cells were chilled and binding assays carried out at 4°C. Cells were incubated for one hour with 25 ng/ml of ^{125}I -bFGF alone, or with the addition of 25 microg/ml of unlabelled bFGF in binding buffer (DMEM,
30 25mM HEPES, 0.05% gelatin). Following incubation with bFGF, cells were washed 2X with ice cold binding buffer. Glycosaminoglycan-bound ^{125}I -bFGF was removed with two rinses with wash buffer (2M NaCl in 20mM

HEPES, pH 7.4). Receptor bound ^{125}I -bFGF was removed by washing 2X with wash buffer (pH 4.0) (Fannon and Nugent (1996) J. Biol. Chem. 271:17949-17956).

5 Numerous growth factors have been shown to bind to heparan sulfate proteoglycans on the cell surface. There is however little information on growth factor binding to chondroitin sulfate proteoglycans. The effects of chondroitinase B and chondroitinase AC on the binding of one such growth factor (bFGF), to fibroblasts was therefore examined. On chondroitinase B-treated cells, the amount of bFGF bound to both cell surface
10 glycosaminoglycans and receptors decreased as the concentration of enzyme increased (Figure 3). Specific binding to glycosaminoglycans was significantly decreased by $51 \pm 6\%$ ($n=3$), at the highest concentration of enzyme used (10 IU/ml). Receptor binding was significantly decreased by $32 \pm 9\%$ and $31 \pm 8\%$ ($n=3$) at 1.0 and 10 IU/ml respectively.

15 Scatchard plot analysis of bFGF binding data found a decrease in the number of receptors on chondroitinase B-treated cells when compared to controls, with no change in binding affinity (Figure 4). Chondroitinase B-treated fibroblasts had $1.8 (\pm 0.6) \times 10^5$ receptors while untreated fibroblasts had $3.0 (\pm 0.8) \times 10^5$ receptors. The binding affinity in chondroitinase-
20 treated fibroblasts was 15.3 ± 3.6 nM, compared to 16.7 ± 2.9 nM in controls, ($n=5$).

Chondroitinase AC was less effective in inhibiting bFGF binding to fibroblasts. Binding of bFGF was unaffected by 0.01 to 1.0 IU/ml of chondroitinase AC, though significant inhibition was found with 10 IU/ml.
25 At 10 IU/ml of chondroitinase AC, specific binding to GAGs and receptors was inhibited by $46 \pm 2\%$, and $54 \pm 3\%$, respectively.

Example 4: Effects on proliferation.

Human dermal fibroblasts were obtained from Clonetics, Inc., San Diego, CA. Cells were cultured in DMEM containing 1% antibiotics and
30 10% serum. The proliferation assay was performed as previously described (Denholm and Phan (1989) Amer. J. Pathol., 134:355-363). Briefly, cells were plated in DMEM w/10% serum; 24 hrs later medium was replaced with

serum free medium, and incubation continued for an additional 24 hrs. Cells were then treated with either serum free DMEM alone, or DMEM containing the indicated concentration of enzyme for 1 hour at 37°C. Following enzyme treatment, cells were rinsed 1X with DMEM, then given DMEM w/10% serum and incubated for 48 hrs. In experiments using bFGF, DMEM containing 2 mg/ml BSA was used, with or without 100 pg/ml bFGF. Controls for each experiment were: (negative) untreated cells incubated in serum free medium, and (positive) untreated cells incubated in DMEM w/10% serum. The number of cells per well was quantitated using the CyQuant assay method from Molecular Probes, Eugene, OR. Fluorescence/well was determined using a CytoFluor Series 4000 fluorescent plate reader (PerSeptive Biosystems) and cell numbers calculated from a standard curve. The average number of cells/well in negative controls was $3.0 \pm 0.3 \times 10^4$, and for positive controls was $9.0 \pm 0.8 \times 10^4$ (mean \pm sem; n = 10). Based on controls for each experiment, data is represented as % Inhibition, where: % Inhibition = $1 - [\text{\#cells/well enzyme-treated}] / [\text{\#cells/well untreated}] \times 100\%$.

Experiments were performed to determine if treatment of fibroblasts with chondroitinase B or chondroitinase AC would have an effect on proliferation of these cells. Proliferation of fibroblasts in response to 10% fetal bovine serum (serum) was inhibited in a dose dependent manner when cells were pretreated for 1 hour with 0.01 to 10 IU/ml of Chondroitinase B (Figure 5A, closed circles). Maximal inhibition of proliferation with chondroitinase B treated fibroblasts was 47 to 63% at 0.3 to 10 IU/ml. Chondroitinase AC treatment of fibroblasts also inhibited the proliferative response to serum in a dose dependent manner (Figure 5B, closed circles). Inhibition of 19 to 44% was found at doses of 1.0 to 10 IU/ml of chondroitinase AC.

Since binding experiments had revealed that treatment with chondroitinase B and chondroitinase AC had decreased bFGF binding to fibroblasts, the fibroblast proliferation experiments were repeated using bFGF in place of serum. Removal of chondroitin sulfate B with

chondroitinase B inhibited the proliferative response to bFGF, in a dose dependent manner (Figure 5A, open circles). Inhibition of proliferation in response to bFGF, however, required higher concentrations of enzyme than were needed to inhibit the response to serum. No inhibition was observed at
5 chondroitinase B concentrations below 1.0 IU/ml; maximal inhibition was $26 \pm 4\%$ at a concentration of 10 IU/ml. There was a significant correlation between the effects of chondroitinase B on bFGF binding to its receptor and the effects on cell proliferation ($r^2 = 0.987$, $p < 0.003$).

Chondroitinase AC treatment of fibroblasts had little effect on the
10 proliferation of fibroblasts in response to bFGF (Figure 5B, open circles). As with bFGF binding, 10 IU/ml of chondroitinase AC was required to detect inhibition of proliferation.

Example 5: Inhibition of collagen synthesis in fibroblasts

The effects of Chondroitinase B on the synthesis and secretion of
15 collagen were examined in an ELISA assay. Human dermal fibroblasts were plated into 96 well plates at a density of 1×10^4 cells/well, in medium with 10% serum. Three days later, medium was changed to serum-free medium containing 50 $\mu\text{g/ml}$ of ascorbic acid, and incubation continued for 24 more hours. Cells were treated for 1 hour with 0 to 10 IU/ml of Chondroitinase B,
20 then washed 1X with serum-free medium, and given fresh medium with ascorbic acid with or without 25 ng/ml TGF-beta. Fibroblasts were then incubated 72 hours at 37°C. Medium was removed from cells, and cells were lysed by adding a solution of 0.02M NH_4OH and 0.5% Triton in phosphate buffered saline (PBS) for 5 mins. The remaining extracellular
25 matrix was washed 2X with PBS. Collagen content of the extracellular matrix was assayed using a direct ELISA, using monoclonal mouse anti-human type I collagen as the primary antibody and horseradish peroxidase conjugated goat anti-mouse antibody as the secondary antibody. Collagen was quantitated by reading absorbance at 450 nm on a multiwell
30 spectrophotometer. The amount of collagen per well was calculated from a standard curve of varying concentrations of human type I collagen.

As shown in Figure 6, Chondroitinase B inhibited collagen secretion and incorporation into the extracellular matrix. The amount of collagen in the matrix of fibroblasts treated with 1 and 10 IU/ml of Chondroitinase B was significantly less than that of untreated cells. This effect was more pronounced with cells for which collagen synthesis had been stimulated with TGF β .

Example 6: Inhibition of fibroblast proliferation in mouse skin organ cultures.

Skin from Flaky skin mice (fsn/fsn) was used in these experiments. Flaky skin mice are a spontaneous mutant strain which develop skin lesions very similar to those seen in human psoriasis. (Sunderberg, et al. (1997) Pathobiology 65:271-286). The skin of these mice is noticeably thickened and scaly by 7 weeks of age. Histological examination shows extensive thickening of the epidermal layers, as well as the dermis. The increase in the dermis is due to the hyperproliferation of fibroblasts and an increase in collagen synthesis by these cells. Any pharmacological agent which decreases dermal thickness may have utility in treating diseases such as psoriasis and scleroderma.

Flaky skin organ cultures were utilized to evaluate the effects of Chondroitinase B on fibroblast proliferation and dermal thickening. Cultures were initiated and maintained, as has been described previously for human skin cultures (Varani, et al. (1994) Amer. J. Pathol. 145:561-573). Skin was obtained from 7 to 9 week old mice. Skin was washed 2X in DMEM containing a 5X concentration of penicillin/streptomycin to prevent contamination of cultures with bacteria. Under sterile conditions, skin was cut into two mm² sections, and one section was placed in each well of 96 well dishes, along with 0, 0.1, 1.0 or 10 IU/ml of Chondroitinase B in Keratinocyte Growth Medium (Clonetics) containing 1.5 mM calcium. These cultures were maintained for 8 days, with a change of medium on days 1, 4 and 6.

On day 0, 3 and 7, some cultures were pulsed with 1 μ Ci of ³H-thymidine and harvested 24 hours later (day 1, 4, and 8). Thymidine labeled

sections were used to assess fibroblast proliferation, measured by the incorporation of thymidine. These cultures were harvested and quantitated as follows: Medium was removed and skin sections washed 2X with ice cold PBS. Ice cold 50% trichloroacetic acid (TCA) was added and cultures
5 incubated at room temperature for 30 mins. TCA was removed and sections washed 2X in ice cold deionized water, and 2X in ice cold 95% ethanol. Sections were dried at room temperature for 3 hours, then individually weighed to obtain mg/ skin section. Sections were placed in scintillation fluid and counted, to quantitate cpm of thymidine incorporated per section,
10 and the cpm/ mg tissue calculated from the weight of each section. For each of four mice, a minimum of 12 sections per time point were used. For each mouse, cpm/mg tissue incorporated by untreated skin (medium alone) was control. The % inhibition in enzyme treated skin was calculated using the control value for each mouse.

15 There was no inhibition of fibroblast proliferation on day 1 or day 4. However, a decrease in proliferation was observed after skin sections were treated with 1 and 10 IU/ml of chondroitinase B for 8 days. As shown in Figure 7, cell proliferation was inhibited by 35% and 48% respectively, in skin treated with 1.0 and 10 IU/ml of chondroitinase B. The effect in skin
20 treated with 10 IU/ml was significant at a level of $p=.002$, determined by ANOVA and Dunnet's group comparisons.

 The effect of Chondroitinase B on skin was also evaluated in stained sections. On the day cultures were initiated (day 0) and days 4 and 8, untreated or enzyme-treated sections were fixed in 10% buffered formalin,
25 embedded in paraffin, sectioned and stained with hematoxylin and eosin for histological examination. Assessment of sectioned skin was based on three sections/ treatment/ mouse/ time point. For each section, a calibrated ocular micrometer was used to measure the thickness of the stratum corneum, the epidermis and the dermis. Three measurements of each layer were taken in
30 different areas of the same section.

 Based on the histological evaluation, there were no significant changes in the thickness of the stratum corneum or the epidermis. There was

however a significant reduction in the thickness of the dermis, the skin layer containing dermal fibroblasts in cultures treated with chondroitinase B. As shown in Figure 8, the thickness of the dermis in skin sections treated with 1.0 and 10 IU/ml of chondroitinase B was 36 and 40% less than that of controls. The reduced thickness of the dermal layer reflects a reduction in the number of fibroblasts, and is in agreement with the decreased cell proliferation, as measured by uptake of tritiated thymidine.

Example 7: Inhibition of the expression of procollagen and TGF β in a mouse model of pulmonary fibrosis.

The effects of Chondroitinase B on the synthesis of type I collagen, and the collagen-promoting cytokine, TGF β , were examined in a mouse model of pulmonary fibrosis. In this model, fibrosis is induced in the lungs of mice, by the intratracheal injection of the antineoplastic drug Bleomoxane®(bleomycin sulfate). Bleomycin-induced fibrosis is very similar to human idiopathic pulmonary fibrosis, as documented by studies of the changes in morphology, biochemistry and mRNA in both mice and humans with this disease. (Phan, S.H. Fibrotic mechanisms in lung disease. In : Immunology of Inflammation, edited by P.A. Ward, New York: Elsevier, 1983, pp121-162; Zhang et. al. (1994) Lab. Invest. 70: 192-202; Phan and Kunkel (1992) Exper. Lung Res. 18:29-43.)

Mice used in these experiments were CBA/J, which were 8 weeks old and approximately 25g. Mice were divided into 3 treatment groups of 6 mice per group. Mice in each group were treated as follows:

	GROUPS		
DAY	1	2	3
0	i.t. saline	i.t. bleomycin 0.025 U in saline	i.t. bleomycin 0.025 U in saline
3,5,7,9,11	i.p. saline	i.p. saline	i.p. Chondroitinase B 20IU in saline

i.t. – intratracheal administration; i.p. = intraperitoneal injection

On Day 21, all mice were killed by lethal injection of sodium pentobarbital. Lungs were flushed with saline to remove blood, and mRNA

extracted, and the expression of procollagen I, and TGF β were assessed as described by Phan and Kunkel (1992; Exper. Lung Res. 18:29-43). The amount of mRNA contained in lungs of mice from the different treatment groups was quantified from densitometry readings from films following

5 Northern blot analysis. The lungs of mice treated with bleomycin followed by Chondroitinase B, contained significantly less mRNA for both procollagen type I and for the collagen synthesis promoting cytokine, TGF β . These results indicate that Chondroitinase B was effective in inhibiting the expression of mRNA for two key proteins which have shown to be greatly

10 increased in fibrotic lungs.

We claim:

1. A method to modulate fibrous tissue formation comprising administering to an individual in need of treatment thereof an effective amount of a dermatan sulfate or chondroitin sulfate degrading enzyme.
2. The method of claim 1 wherein the enzyme is selected from the group consisting of bacterial dermatan or chondroitin sulfate degrading enzyme and is selected from the group consisting of chondroitinase AC from *Flavobacterium heparinum*, chondroitinase B from *Flavobacterium heparinum*, chondroitin sulfate degrading enzymes from *Bacteroides* species, chondroitin sulfate degrading enzymes from *Proteus vulgaris*, chondroitin sulfate degrading enzymes from *Micrococcus*, chondroitin sulfate degrading enzymes from *Vibrio* species, chondroitin sulfate degrading enzymes from *Arthrobacter aurescens*, arylsulfatase B, N-acetylgalactosamine-6-sulfatase and iduronate sulfatase from mammalian cells, these enzymes expressed from recombinant nucleotide sequences in bacteria and combinations thereof.
3. The method of claim 1 wherein the enzyme is a mammalian enzyme.
4. The method of claim 1 wherein the enzyme is a bacterial enzyme.
5. The method of claim 4 wherein the chondroitinase is chondroitinase B.
6. The method of claim 1 wherein the individual has a skin disorder.
7. The method of claim 6 wherein the skin disorder is scleroderma or psoriasis.
8. The method of claim 1 wherein the individual has keloid scarring or is at risk of keloid scarring, or has pulmonary fibrosis.
9. The method of claim 1 wherein the enzyme is administered systemically.
10. The method of claim 1 wherein the enzyme is administered topically or locally at or adjacent to a site in need of treatment.

11. The method of claim 1 wherein the enzyme is administered in a controlled and/or sustained release formulation.

12. A formulation for administration to an individual in need of treatment thereof for a disorder involving organ fibrosis, the formulation comprising an effective amount of a dermatan or chondroitin sulfate degrading enzyme to inhibit fibrosis, wherein the dosage is different than the amount effective for wound healing, and a pharmaceutically acceptable carrier.

13. The formulation of claim 12 wherein the enzyme is selected from the group consisting of bacterial chondroitin sulfate degrading enzyme and is selected from the group consisting of chondroitinase AC from *Flavobacterium heparinum*, chondroitinase B from *Flavobacterium heparinum*, chondroitin sulfate degrading enzymes from *Bacteroides* species, chondroitin sulfate degrading enzymes from *Proteus vulgaris*, chondroitin sulfate degrading enzymes from *Micrococcus*, chondroitin sulfate degrading enzymes from *Vibrio* species, chondroitin sulfate degrading enzymes from *Arthrobacter aureus*, these enzymes expressed from recombinant nucleotide sequences in bacteria and combinations thereof.

14. The formulation of claim 12 wherein the enzyme is a mammalian enzyme.

15. The formulation of claim 12 wherein the enzyme is a bacterial chondroitinase.



16. The formulation of claim 15 wherein the chondroitinase is chondroitinase B.



17. The formulation of claim 12 wherein the enzyme is in a controlled, sustained release formulation.

18. The formulation of claim 12 in a dosage effective to collagen synthesis.



19. The formulation of claim 12 in an effective aerosol formulation for delivery to the lungs.

1/6




**FIG. 1A****FIG. 1B**

**FIG. 2****FIG. 3A**



3/6



**FIG. 3B****FIG. 4**

4/6

**FIG. 5A****FIG. 5B****FIG. 6**

5/6

**FIG. 7****FIG. 8**

**FIG. 9A****FIG. 9B**

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/32399

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/46 A61K38/51 A61P17/00 A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Data, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; DONATI L ET AL: "Treatment of hypertrophic and keloid cicatrices with thiomucase". Il trattamento delle cicatrici ipertrofiche e cheloidee mediante thiomucase." retrieved from STN Database accession no. 76196588 XP002169931 abstract & MINERVA CHIRURGICA, (1975 MAR 31) 30 (6) 326-33. ,</p>	1,6,8-11

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

18 June 2001

Date of mailing of the international search report

28/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 691 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Stein, A

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/32399

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 695 752 A (IMAI YASUYUKI ET AL) 9 December 1997 (1997-12-09) column 6, line 6 -column 7, line 5 column 13, line 17 -column 14, line 4 column 15, line 12 -column 16, line 62 -----	1-7,9-11
X	WO 98 46258 A (BETH ISRAEL HOSPITAL) 22 October 1998 (1998-10-22) the whole document -----	1-5,8-19
X	WO 99 48478 A (YACOBY ZEEVI ORON ;FRIEDMAN MARK M (IL); INSIGHT STRATEGY & MARKET) 30 September 1999 (1999-09-30) the whole document -----	1-5,8-19
X	WO 95 13091 A (INT TECH MANAGEMENT ASS ;RATCLIFFE ANTHONY (US); UNIV COLUMBIA (US) 18 May 1995 (1995-05-18) page 7, line 22 -page 8, line 4 page 8, line 31 -page 9, line 17 page 12, line 16 -page 14, line 8 page 17, line 26 - line 27 claims 1,16,17 -----	1-4, 9-15,17, 18
A	DENHOLM ELIZABETH M: "Inhibition of fibroblast proliferation by chondroitinase AC(CAC) and chondroitinase B(CB)." FASEB JOURNAL, vol. 12, no. 5, 20 March 1998 (1998-03-20), page A948 XP002169930 Annual Meeting of the Professional Research Scientists on Experimental Biology 98, Part II; San Francisco, California, USA; April 18-22, 1998 ISSN: 0892-6638 the whole document -----	1-19
T	DENHOLM ELIZABETH M ET AL: "Inhibition of human dermal fibroblast proliferation by removal of dermatan sulfate." EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 400, no. 2-3, 2000, pages 145-153, XP001009717 ISSN: 0014-2999 the whole document -----	1-19

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 1,3,4,6-12,14,17-19 all partially

Present claims 1,3,4,6-12,14,17-19 relate to an enzyme defined by reference to a desirable property, namely its dermatan sulfate or chondroitin sulfate degrading activity. However these claims do not contain any structural or essential characteristics of the enzyme. The claims cover all enzymes having this property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such enzymes. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the enzyme by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the enzymes mentioned in the description at page 6 line 18- page 8 line 17 and in claims 2,5,13,15 and 16 of the application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/32399

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5695752 A	09-12-1997	US 5925349 A	20-07-1999
		AU 700369 B	07-01-1999
		AU 2120995 A	03-10-1995
		CA 2185324 A	21-09-1995
		EP 0750511 A	02-01-1997
		JP 10500939 T	27-01-1998
		WO 9524920 A	21-09-1995
		AU 4859793 A	12-04-1994
		WO 9406442 A	31-03-1994
		US 5580862 A	03-12-1996
		AU 1255695 A	06-06-1995
		WO 9513819 A	26-05-1995
		US 5489578 A	06-02-1996
		US 5783693 A	21-07-1998
WO 9846258 A	22-10-1998	AU 6897198 A	11-11-1998
		US 6200564 B	13-03-2001
WO 9948478 A	30-09-1999	US 6153187 A	28-11-2000
		AU 3107799 A	18-10-1999
WO 9513091 A	18-05-1995	AU 1176595 A	29-05-1995
		US 5916557 A	29-06-1999